Extended Data Fig. 8: B16 tumour growth in mice depleted of CD8+ or NK cells.
From: Gasdermin E suppresses tumour growth by activating anti-tumour immunity
a, Experimental scheme and growth of empty vector or mGSDME-positive B16 tumours in mice depleted of CD8+ T cells (n = 6 mice per group) or NK cells (n = 6 mice per group) or treated with an isotype control antibody. Empty vector, n = 6 mice per group; mGSDME-positive, n = 7 mice per group. b, c, Antibody depletion was verified by flow cytometry using peripheral blood mononuclear cells (PBMCs) on day 7 after tumour challenge or using TILs at the time of necropsy. Representative flow plots show depletion of CD8+ T cells (top) or NK cells (bottom) in the peripheral blood (b) and tumours (c) of mice bearing B16 empty vector or B16 GSDME tumours treated with isotype control, anti-CD8 or anti-NK1.1 antibodies. The area under the curve of tumour growth curves was compared by one-way ANOVA with Holm–Sidak correction for type I error. Data are mean + s.e.m. All data are representative of two independent experiments.
